Decreased Levels of Low-Density Lipoprotein Cholesterol (LDL-C) with the Use of Low and Moderate-Intensity Statins in Type 2 Diabetic Patients Treated in A Community Hospital
Article Sidebar
Main Article Content
Abstract
BACKGROUND: The aim of this study was to determine the efficacy of low-intensity and moderate-intensity statin drugs in reducing LDL-C levels in type 2 diabetic patients, which could serve as a guideline for the selection of drugs for this group.
OBJECTIVES: To study the reduction of LDL-C levels when using low and moderate intensity statin drugs for type 2 diabetic patients in a community hospital.
METHODS: This retrospective cross-sectional study collected data during a 3-year period (2018-2020). The data was collected from diabetic patients, who began treatment with low-intensity and moderate-intensity statin drugs during the period of 1 January 2018-31 December 2020. This study compared the reductions in the LDL-C levels before and after at least 3 months of treatment.
RESULTS: The subjects consisted of 71 patients. Of the subjects, 36 patients (50.7%) received moderate-intensity statin, while 35 patients (49.3%) received low-intensity statin. For the moderate-intensity and low-intensity statin treatments, the mean pre-treatment LDL-C levels were 163.6±44.3 and 144.6±24.7 mg/dL, respectively, while the after-treatment levels were 90.2±29.9 and 91.8±29.6 mg/dL. In addition, the mean reductions in LDL-C levels were 43.4±19.1 (p<0.001) and 36.0±19.1 (p<0.001), respectively.
CONCLUSIONS: Low intensity statin can reduce LDL-C in type 2 diabetic patients more than 30%, which is greater than the average percentage of LDL-C reductions according to the statin intensity guidelines established by the ACC/AHA in 2013. Moderate-intensity statins did not differ (30-50%).
Thaiclinicaltrials.org number, TCTR20230101001
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Aekplakorn W. Thai national health examination survey, NHES V [Internet]. 2016 [cited 2021 Dec 18]. Available from: https://kb.hsri.or.th/dspace/bitstream/handle/11228/4604/uc_vichai.pdf?sequence=1&isAllowed=y
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733):2215-22.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670-81.
Thai Atherosclerosis Society. 2016 RCPT clinical practice guideline on pharmacologic therapy of dyslipidemia for atherosclerotic cardiovascular disease prevention. Bangkok: Thai Atherosclerosis Society; 2017.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;63 (25 Pt B) :2889-934.
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99:410-4.
Thongtang N, Sitthananun C, Sriussadaporn S, Nitiyanant W. Efficacy of low- and moderate-intensity statins for achieving low-density lipoprotein cholesterol targets in Thai type 2 diabetic patients. J Diabetes Metab Disord [Internet]. 2017 [cited 2021 Dec 18];16:6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307884/pdf/40200_2017_Article_290.pdf
Wu CC, Sy R, Tanphaichitr V, Hin ATT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. J Formos Med Assoc 2002;101:478-87.
Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.